{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:51:29Z","timestamp":1793055089773,"version":"4.5.0"},"reference-count":76,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,21]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Cutaneous T-cell lymphoma (CTCL) remains a challenging disease due to its significant heterogeneity, therapy resistance, and relentless progression. Multiomics technologies offer the potential to provide uniquely precise views of disease progression and response to therapy. Here, we present a comprehensive multiomics view of CTCL clonal evolution, incorporating exome, whole-genome, epigenome, bulk, single-cell T-cell receptor, and single-cell RNA sequencing of 99 clinically annotated serial skin, peripheral blood, and lymph node samples from 34 patients with CTCL. We leveraged this extensive data set to define the molecular underpinnings of CTCL progression in individual patients at single-cell resolution with the goal of identifying clinically useful biomarkers and therapeutic targets. Our studies identified recurrent progression-associated clonal genomic alterations; we highlight mutation of CCR4, phosphoinositide 3-kinase inhibitor signaling, and programmed cell death protein 1 (PD-1) checkpoint pathways as evasion tactics deployed by malignant T cells. We identified a gain-of-function mutation in STAT3 (D661Y) and demonstrated, using cleavage under targets and release using nuclease (CUT&amp;RUN) and RNA sequencing, that it enhances binding to and transcription of genes in Rho GTPase pathways. With our previous work implicating this pathway in histone deacetylase inhibitor\u2013resistant CTCL, these data provide further support for a previously unrecognized role for Rho GTPase pathway dysregulation in CTCL progression. Recurrent progression-associated mutations were common in the epigenetic modifier EZH2, suggesting that EZH2 inhibition may benefit patients with CTCL. Our findings support an approach in which genomic analysis is widely used for improved disease monitoring, biomarker-informed clinical trial design, and genome-guided therapeutic decision-making. Moreover, these molecular changes present new opportunities for therapeutic targeting in this challenging and incurable cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025029012","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T20:41:40Z","timestamp":1770669700000},"page":"2503-2517","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":4,"title":["Multiomic study of cutaneous T-cell lymphoma reveals single-cell clonal evolution in progression and therapy resistance"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9600-588X","authenticated-orcid":false,"given":"Hannah K.","family":"Dorando","sequence":"first","affiliation":[{"name":"1Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared M.","family":"Andrews","sequence":"additional","affiliation":[{"name":"1Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0003-1883","authenticated-orcid":false,"given":"Oam U.","family":"Khatavkar","sequence":"additional","affiliation":[{"name":"1Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1427-6342","authenticated-orcid":false,"given":"Nicholas C.","family":"Borcherding","sequence":"additional","affiliation":[{"name":"1Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia","family":"Korshunova","sequence":"additional","affiliation":[{"name":"1Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7576-1409","authenticated-orcid":false,"given":"Gabriela","family":"Hakeman","sequence":"additional","affiliation":[{"name":"1Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Panigassi","sequence":"additional","affiliation":[{"name":"1Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuong","family":"Vo","sequence":"additional","affiliation":[{"name":"1Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruei-yuan","family":"Tu","sequence":"additional","affiliation":[{"name":"1Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7998-4363","authenticated-orcid":false,"given":"Diep","family":"Tran","sequence":"additional","affiliation":[{"name":"1Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaz C.","family":"Quinn","sequence":"additional","affiliation":[{"name":"1Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Schmidt","sequence":"additional","affiliation":[{"name":"1Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jahnavi","family":"Aluri","sequence":"additional","affiliation":[{"name":"2Department of Pediatrics, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6892-1880","authenticated-orcid":false,"given":"Michael T.","family":"Harmon","sequence":"additional","affiliation":[{"name":"2Department of Pediatrics, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1224-3478","authenticated-orcid":false,"given":"Marcus P.","family":"Watkins","sequence":"additional","affiliation":[{"name":"3Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Frank","sequence":"additional","affiliation":[{"name":"3Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5696-172X","authenticated-orcid":false,"given":"Megan A.","family":"Cooper","sequence":"additional","affiliation":[{"name":"2Department of Pediatrics, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3745-6223","authenticated-orcid":false,"given":"Amy C.","family":"Musiek","sequence":"additional","affiliation":[{"name":"4Division of Dermatology, Department of Medicine, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5744-0670","authenticated-orcid":false,"given":"Neha","family":"Mehta-Shah","sequence":"additional","affiliation":[{"name":"3Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8832-3661","authenticated-orcid":false,"given":"Jacqueline E.","family":"Payton","sequence":"additional","affiliation":[{"name":"1Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2026052111215793000_bib1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41572-021-00296-9","article-title":"Cutaneous T cell lymphoma","volume":"7","author":"Dummer","year":"2021","journal-title":"Nat Rev Dis Primer"},{"key":"2026052111215793000_bib2","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ebiom.2019.07.053","article-title":"Novel cell adhesion\/migration pathways are predictive markers of HDAC inhibitor resistance in cutaneous T cell lymphoma","volume":"46","author":"Andrews","year":"2019","journal-title":"EBioMedicine"},{"issue":"5","key":"2026052111215793000_bib3","doi-asserted-by":"crossref","first-page":"522","DOI":"10.6004\/jnccn.2020.0022","article-title":"NCCN guidelines insights: primary cutaneous lymphomas, version 2.2020","volume":"18","author":"Mehta-Shah","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"2026052111215793000_bib4","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1182\/bloodadvances.2021005991","article-title":"Single-cell analysis of S\u00e9zary syndrome reveals novel markers and shifting gene profiles associated with treatment","volume":"7","author":"Borcherding","year":"2023","journal-title":"Blood Adv"},{"issue":"10","key":"2026052111215793000_bib5","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1158\/1078-0432.CCR-18-3309","article-title":"Single-cell profiling of cutaneous T-cell lymphoma reveals underlying heterogeneity associated with disease progression","volume":"25","author":"Borcherding","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"16","key":"2026052111215793000_bib6","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1182\/bloodadvances.2018022608","article-title":"Single-cell heterogeneity in S\u00e9zary syndrome","volume":"2","author":"Buus","year":"2018","journal-title":"Blood Adv"},{"issue":"9","key":"2026052111215793000_bib7","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/ng.3356","article-title":"Genomic landscape of cutaneous T cell lymphoma","volume":"47","author":"Choi","year":"2015","journal-title":"Nat Genet"},{"issue":"12","key":"2026052111215793000_bib8","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/ng.3442","article-title":"The mutational landscape of cutaneous T cell lymphoma and S\u00e9zary syndrome","volume":"47","author":"da Silva Almeida","year":"2015","journal-title":"Nat Genet"},{"issue":"5","key":"2026052111215793000_bib9","doi-asserted-by":"crossref","first-page":"e1306618","DOI":"10.1080\/2162402X.2017.1306618","article-title":"Gene expression analysis in cutaneous T-cell lymphomas (CTCL) highlights disease heterogeneity and potential diagnostic and prognostic indicators","volume":"6","author":"Litvinov","year":"2017","journal-title":"Oncoimmunology"},{"issue":"4","key":"2026052111215793000_bib10","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1182\/blood-2014-11-611194","article-title":"Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides","volume":"126","author":"McGirt","year":"2015","journal-title":"Blood"},{"issue":"14","key":"2026052111215793000_bib11","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1182\/blood.2020009655","article-title":"Integrated genomic analyses of cutaneous T cell lymphomas reveal the molecular bases for disease heterogeneity","volume":"138","author":"Park","year":"2021","journal-title":"Blood"},{"issue":"12","key":"2026052111215793000_bib12","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1182\/blood-2017-02-768234","article-title":"Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E)","volume":"130","author":"Park","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2026052111215793000_bib13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ccell.2017.05.008","article-title":"Chromatin accessibility landscape of cutaneous T cell lymphoma and dynamic response to HDAC inhibitors","volume":"32","author":"Qu","year":"2017","journal-title":"Cancer Cell"},{"issue":"5","key":"2026052111215793000_bib14","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1158\/2159-8290.CD-21-1207","article-title":"Genomic and single-cell landscape reveals novel drivers and therapeutic vulnerabilities of transformed cutaneous T-cell lymphoma","volume":"12","author":"Song","year":"2022","journal-title":"Cancer Discov"},{"issue":"12","key":"2026052111215793000_bib15","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/ng.3444","article-title":"Genomic profiling of S\u00e9zary syndrome identifies alterations of key T cell signaling and differentiation genes","volume":"47","author":"Wang","year":"2015","journal-title":"Nat Genet"},{"issue":"18","key":"2026052111215793000_bib16","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.3390\/cancers14184466","article-title":"Unraveling the structural variations of early-stage mycosis fungoides\u2014CD3 based purification and third generation sequencing as novel tools for the genomic landscape in CTCL","volume":"14","author":"Hain","year":"2022","journal-title":"Cancers"},{"issue":"24","key":"2026052111215793000_bib17","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","article-title":"Immune escape of relapsed AML cells after allogeneic transplantation","volume":"379","author":"Christopher","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"2026052111215793000_bib18","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1158\/2643-3230.BCD-21-0050","article-title":"Genetic and transcriptional contributions to relapse in normal karyotype acute myeloid leukemia","volume":"3","author":"Petti","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"2026052111215793000_bib19","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1038\/s41467-019-11591-1","article-title":"A general approach for detecting expressed mutations in AML cells using single cell RNA-sequencing","volume":"10","author":"Petti","year":"2019","journal-title":"Nat Commun"},{"issue":"7","key":"2026052111215793000_bib20","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s10875-015-0187-8","article-title":"The Ying and Yang of STAT3 in human disease","volume":"35","author":"Vogel","year":"2015","journal-title":"J Clin Immunol"},{"issue":"12","key":"2026052111215793000_bib21","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1182\/blood.2021015330","article-title":"Aberrant function of pathogenic STAT3 mutant proteins is linked to altered stability of monomers and homodimers","volume":"141","author":"Kasembeli","year":"2023","journal-title":"Blood"},{"issue":"12","key":"2026052111215793000_bib22","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1016\/j.immuni.2022.11.001","article-title":"STAT3 gain-of-function mutations connect leukemia with autoimmune disease by pathological NKG2Dhi CD8+ T cell dysregulation and accumulation","volume":"55","author":"Masle-Farquhar","year":"2022","journal-title":"Immunity"},{"issue":"11","key":"2026052111215793000_bib23","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.3390\/cancers11111757","article-title":"Structural implications of STAT3 and STAT5 SH2 domain mutations","volume":"11","author":"de Araujo","year":"2019","journal-title":"Cancers"},{"issue":"4","key":"2026052111215793000_bib24","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2014-09-602763","article-title":"Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations","volume":"125","author":"Milner","year":"2015","journal-title":"Blood"},{"issue":"50","key":"2026052111215793000_bib25","doi-asserted-by":"crossref","first-page":"21499","DOI":"10.1073\/pnas.1016147107","article-title":"Reversible methylation of promoter-bound STAT3 by histone-modifying enzymes","volume":"107","author":"Yang","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"2026052111215793000_bib26","doi-asserted-by":"crossref","first-page":"e173602","DOI":"10.1172\/JCI173602","article-title":"Induced CD8\u03b1 identifies human NK cells with enhanced proliferative fitness and modulates NK cell activation","volume":"134","author":"Cubitt","year":"2024","journal-title":"J Clin Invest"},{"key":"2026052111215793000_bib27","doi-asserted-by":"publisher","DOI":"10.48550\/arXiv.1802.03426","article-title":"UMAP: uniform manifold approximation and projection for dimension reduction","author":"McInnes","year":"9  2020","journal-title":"arXiv"},{"issue":"12","key":"2026052111215793000_bib28","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1158\/1078-0432.CCR-14-3322","article-title":"The use of transcriptional profiling to improve personalized diagnosis and management of cutaneous T-cell lymphoma (CTCL)","volume":"21","author":"Litvinov","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2026052111215793000_bib29","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/bjd.18481","article-title":"Revisiting the initial diagnosis and blood staging of mycosis fungoides and S\u00e9zary syndrome with the KIR3DL2 marker","volume":"182","author":"Roelens","year":"2020","journal-title":"Br J Dermatol"},{"issue":"2","key":"2026052111215793000_bib30","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1365-2133.2009.09587.x","article-title":"T-plastin (PLS3) gene expression differentiates S\u00e9zary syndrome from mycosis fungoides and inflammatory skin diseases and can serve as a biomarker to monitor disease progression","volume":"162","author":"Tang","year":"2010","journal-title":"Br J Dermatol"},{"issue":"33","key":"2026052111215793000_bib31","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.18632\/oncotarget.5742","article-title":"Dysregulation of the TOX-RUNX3 pathway in cutaneous T-cell lymphoma","volume":"10","author":"Dulmage","year":"2019","journal-title":"Oncotarget"},{"issue":"22","key":"2026052111215793000_bib32","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2014-09-598995","article-title":"KIR3DL2 is a coinhibitory receptor on S\u00e9zary syndrome malignant T cells that promotes resistance to activation-induced cell death","volume":"124","author":"Thonnart","year":"2014","journal-title":"Blood"},{"key":"2026052111215793000_bib33","doi-asserted-by":"crossref","first-page":"e00191","DOI":"10.1016\/j.plabm.2020.e00191","article-title":"Validation and interpretation of IGH and TCR clonality testing by Ion Torrent S5 NGS for diagnosis and disease monitoring in B and T cell cancers","volume":"22","author":"Lay","year":"2020","journal-title":"Pract Lab Med"},{"key":"2026052111215793000_bib34","doi-asserted-by":"crossref","first-page":"47","DOI":"10.12688\/f1000research.22139.1","article-title":"scRepertoire: an R-based toolkit for single-cell immune receptor analysis","volume":"9","author":"Borcherding","year":"2020","journal-title":"F1000Res"},{"issue":"1","key":"2026052111215793000_bib35","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/bjh.13400","article-title":"Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data","volume":"170","author":"Bates","year":"2015","journal-title":"Br J Haematol"},{"issue":"6","key":"2026052111215793000_bib36","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s40257-018-0380-7","article-title":"Current status of HDAC inhibitors in cutaneous T-cell lymphoma","volume":"19","author":"Lopez","year":"2018","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"2026052111215793000_bib37","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13148-023-01531-8","article-title":"Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL)","volume":"15","author":"Lu","year":"2023","journal-title":"Clin Epigenetics"},{"issue":"1","key":"2026052111215793000_bib38","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12943-019-1127-7","article-title":"Role of HDACs in normal and malignant hematopoiesis","volume":"19","author":"Wang","year":"2020","journal-title":"Mol Cancer"},{"issue":"29","key":"2026052111215793000_bib39","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"2026052111215793000_bib40","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1182\/bloodadvances.2020002371","article-title":"Pembrolizumab in mycosis fungoides with PD-L1 structural variants","volume":"5","author":"Beygi","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"2026052111215793000_bib41","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.19.01056","article-title":"Pembrolizumab in relapsed and refractory mycosis fungoides and S\u00e9zary syndrome: a multicenter phase II study","volume":"38","author":"Khodadoust","year":"2020","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026052111215793000_bib42","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-\u03b4,\u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2026052111215793000_bib43","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1182\/blood-2018-99-115241","article-title":"The combination of duvelisib, a PI3K-\u03b4,\u03b3 inhibitor, and romidepsin is highly active in relapsed\/refractory peripheral T-cell lymphoma with low rates of transaminitis: results of parallel multicenter, phase 1 combination studies with expansion cohorts [abstract]","volume":"132","author":"Horwitz","year":"2018","journal-title":"Blood"},{"issue":"26","key":"2026052111215793000_bib44","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.1182\/blood.2021014468","article-title":"Resistance to mogamulizumab is associated with loss of CCR4 in cutaneous T-cell lymphoma","volume":"139","author":"Beygi","year":"2022","journal-title":"Blood"},{"issue":"5","key":"2026052111215793000_bib45","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nm.3165","article-title":"IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase-driven tumors","volume":"19","author":"Jameson","year":"2013","journal-title":"Nat Med"},{"issue":"12","key":"2026052111215793000_bib46","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ncb3441","article-title":"Agonist-stimulated phosphatidylinositol-3,4,5-trisphosphate generation by scaffolded phosphoinositide kinases","volume":"18","author":"Choi","year":"2016","journal-title":"Nat Cell Biol"},{"issue":"6","key":"2026052111215793000_bib47","doi-asserted-by":"crossref","first-page":"e202205062","DOI":"10.1083\/jcb.202205062","article-title":"The IQGAP scaffolds: critical nodes bridging receptor activation to cellular signaling","volume":"222","author":"Thines","year":"2023","journal-title":"J Cell Biol"},{"issue":"8","key":"2026052111215793000_bib48","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/nrm.2016.67","article-title":"Regulating Rho GTPases and their regulators","volume":"17","author":"Hodge","year":"2016","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6916","key":"2026052111215793000_bib49","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/nature01148","article-title":"Rho GTPases in cell biology","volume":"420","author":"Etienne-Manneville","year":"2002","journal-title":"Nature"},{"key":"2026052111215793000_bib50","doi-asserted-by":"crossref","first-page":"8470","DOI":"10.1038\/ncomms9470","article-title":"Genomic analyses reveal recurrent mutations in epigenetic modifiers and the JAK-STAT pathway in S\u00e9zary syndrome","volume":"6","author":"Kiel","year":"2015","journal-title":"Nat Commun"},{"issue":"21","key":"2026052111215793000_bib51","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.4161\/15384101.2014.965061","article-title":"Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression","volume":"13","author":"Netchiporouk","year":"2014","journal-title":"Cell Cycle"},{"issue":"5","key":"2026052111215793000_bib52","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ccell.2020.04.004","article-title":"Mutant EZH2 induces a pre-malignant lymphoma niche by reprogramming the immune response","volume":"37","author":"B\u00e9guelin","year":"2020","journal-title":"Cancer Cell"},{"issue":"5","key":"2026052111215793000_bib53","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ccr.2013.04.011","article-title":"EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation","volume":"23","author":"B\u00e9guelin","year":"2013","journal-title":"Cancer Cell"},{"issue":"18","key":"2026052111215793000_bib54","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2013-04-496893","article-title":"EZH2 mutations are frequent and represent an early event in follicular lymphoma","volume":"122","author":"B\u00f6d\u00f6r","year":"2013","journal-title":"Blood"},{"issue":"11","key":"2026052111215793000_bib55","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.clml.2019.08.010","article-title":"EZH2 overexpression in multiple myeloma: prognostic value, correlation with clinical characteristics, and possible mechanisms","volume":"19","author":"Goldsmith","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"2026052111215793000_bib56","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-019-0814-6","article-title":"EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications","volume":"12","author":"Li","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"2","key":"2026052111215793000_bib57","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat Genet"},{"issue":"12","key":"2026052111215793000_bib58","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1182\/blood.V97.12.3896","article-title":"Coexpression of BMI-1 and EZH2 Polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma","volume":"97","author":"van Kemenade","year":"2001","journal-title":"Blood"},{"issue":"24","key":"2026052111215793000_bib59","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.1182\/blood-2010-04-280149","article-title":"EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis","volume":"116","author":"Velichutina","year":"2010","journal-title":"Blood"},{"issue":"13","key":"2026052111215793000_bib60","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1073\/pnas.1503152112","article-title":"STAT3-driven transcription depends upon the dimethylation of K49 by EZH2","volume":"112","author":"Dasgupta","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2026052111215793000_bib61","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ccr.2013.04.008","article-title":"Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells","volume":"23","author":"Kim","year":"2013","journal-title":"Cancer Cell"},{"issue":"7078","key":"2026052111215793000_bib62","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nature04431","article-title":"The Polycomb group protein EZH2 directly controls DNA methylation","volume":"439","author":"Vir\u00e9","year":"2006","journal-title":"Nature"},{"issue":"10","key":"2026052111215793000_bib63","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1016\/j.celrep.2018.11.035","article-title":"Polycomb- and methylation-independent roles of EZH2 as a transcription activator","volume":"25","author":"Kim","year":"2018","journal-title":"Cell Rep"},{"issue":"6","key":"2026052111215793000_bib64","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/nm.4092","article-title":"An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation","volume":"22","author":"Souroullas","year":"2016","journal-title":"Nat Med"},{"issue":"7","key":"2026052111215793000_bib65","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2016-01-690701","article-title":"EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer\/T-cell lymphoma","volume":"128","author":"Yan","year":"2016","journal-title":"Blood"},{"key":"2026052111215793000_bib66","doi-asserted-by":"crossref","first-page":"1233953","DOI":"10.3389\/fonc.2023.1233953","article-title":"Non-canonical functions of EZH2 in cancer","volume":"13","author":"Zimmerman","year":"2023","journal-title":"Front Oncol"},{"issue":"46","key":"2026052111215793000_bib67","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1038\/s41388-022-02492-7","article-title":"Ezh2Y641F mutations co-operate with Stat3 to regulate MHC class I antigen processing and alter the tumor immune response in melanoma","volume":"41","author":"Zimmerman","year":"2022","journal-title":"Oncogene"},{"issue":"suppl 1","key":"2026052111215793000_bib68","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1182\/blood-2022-166991","article-title":"Tazemetostat in combination with lenalidomide and rituximab in patients with relapsed\/refractory follicular lymphoma: phase 1b results of symphony-1 [abstract]","volume":"140","author":"Batlevi","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2026052111215793000_bib69","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13045-020-00937-8","article-title":"EZH2: a novel target for cancer treatment","volume":"13","author":"Duan","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"5","key":"2026052111215793000_bib70","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s12185-024-03834-9","article-title":"Tazemetostat for relapsed\/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II study","volume":"120","author":"Izutsu","year":"2024","journal-title":"Int J Hematol"},{"issue":"10","key":"2026052111215793000_bib71","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood.2022016862","article-title":"An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia\/lymphoma","volume":"141","author":"Izutsu","year":"2023","journal-title":"Blood"},{"issue":"7427","key":"2026052111215793000_bib72","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature11606","article-title":"EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations","volume":"492","author":"McCabe","year":"2012","journal-title":"Nature"},{"issue":"11","key":"2026052111215793000_bib73","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol"},{"issue":"21","key":"2026052111215793000_bib74","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J Clin Oncol"},{"issue":"32","key":"2026052111215793000_bib75","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma","volume":"27","author":"Piekarz","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026052111215793000_bib76","doi-asserted-by":"crossref","first-page":"e3002038","DOI":"10.1371\/journal.pbio.3002038","article-title":"Combating castration-resistant prostate cancer by co-targeting the epigenetic regulators EZH2 and HDAC","volume":"21","author":"Schade","year":"2023","journal-title":"PLoS Biol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/21\/2503\/2521286\/blood_bld-2025-029012-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/21\/2503\/2521286\/blood_bld-2025-029012-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:22:13Z","timestamp":1779376933000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/21\/2503\/566464\/Multiomic-study-of-cutaneous-T-cell-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":76,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2026,5,21]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025029012","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,21]]},"published":{"date-parts":[[2026,5,21]]}}}